Physician profile
Laila S Malad
NPI 1376763565
$5,796.69
in general payments reported to CMS, 2019-2025
17 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Diagnostic Neuroimaging (Psychiatry & Neurology) provider received nationally (typical 2025 total: $1,744).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,877 · 2020: $154 · 2021: $941 · 2022: $353 · 2023: $994 · 2024: $1,004 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,397 · Education: $73.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.27 |
| Education | $73.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $831.77 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $767.20 | 2019-2025 | Rexulti |
| Allergan, INC. | $718.59 | 2019-2020 | |
| Alkermes, INC. | $533.81 | 2019-2025 | Lybalvi |
| Axsome Therapeutics, INC. | $461.03 | 2023-2025 | Auvelity |
| Tris Pharma INC | $441.92 | 2021-2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $438.48 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $421.90 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $274.46 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $228.86 | 2019-2025 | Austedo Xr |
| Amarin Pharma, INC. | $128.35 | 2019 | |
| Therapeuticsmd, INC. | $124.58 | 2019 | |
| Cardinal Health 200 LLC | $92.92 | 2019 | |
| Avanir Pharmaceuticals, INC. | $91.55 | 2019 | |
| Vertiflex, INC. | $84.17 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $83.33 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $73.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laila Malad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.